Invera Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Invera Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.2K	Hold	20,000	–	–	0.02%	98
2025 Q4	$23K	Hold	20,000	–	–	0.01%	90
2025 Q3	$27K	Hold	20,000	–	–	0.02%	87
2025 Q2	$18.9K	Hold	20,000	–	–	0.01%	84
2025 Q1	$9.22K	Buy	+20,000	New	+$12.6K	0.01%	90

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Invera Wealth Advisors's LXRX Position: Q1 2026 in Review

Invera Wealth Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 20,000 shares worth $31.2K. The position accounts for 0.02% of the portfolio, ranked #98.

Invera Wealth Advisors first reported a position in LXRX in Q1 2025 and has held it in 5 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Invera Wealth Advisors held 20,000 shares of Lexicon Pharmaceuticals worth $31.2K as of Q1 2026.
Invera Wealth Advisors left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
Lexicon Pharmaceuticals made up 0.02% of Invera Wealth Advisors's portfolio in Q1 2026, its #98 holding.
Invera Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Invera Wealth Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.